Epidemiology of cytomegalovirus infection in pregnancy in Israel: Real-world data from a large healthcare organization.
cohort studies
cytomegalovirus infections
epidemiology
pregnancy
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
30
09
2021
received:
20
05
2021
accepted:
16
10
2021
pubmed:
20
10
2021
medline:
9
2
2022
entrez:
19
10
2021
Statut:
ppublish
Résumé
Congenital cytomegalovirus infection (cCMVi) is the leading cause of nonhereditary sensorineural hearing loss among newborns. Women newly acquiring cytomegalovirus infection (CMVi) during pregnancy have the highest risk of vertical transmission. This study aimed to describe the epidemiology of CMVi in pregnancy in a large healthcare database. A retrospective cohort study was performed using the Maccabi Healthcare Services database (Israel). Women aged 18-44 years old on July 1, 2013 with no record of pregnancy in the prior 6 months were followed through December 31, 2017 for first pregnancy occurrence. Pregnancy outcomes (live birth, spontaneous/therapeutic abortions, stillbirth, and uncertain outcomes) were captured. CMV test results were obtained to assess serostatus at the start of pregnancy (SoP) and primary CMV infection (CMVi) during pregnancy. Associations of demographic and reproductive factors with pCMVi were investigated (multivariable logistic regression). The study included 84 699 pregnant women (median age = 31 years; interquartile range = 28-35). Live birth, fetal loss, and uncertain pregnancy outcomes accounted for 76.8%, 18.2%, and 5.0%, respectively. The seroprevalence of CMV at the start of pregnancy in this cohort was 63.4% (95% confidence interval [CI]: 63.1-63.7). Among seronegative women with available test results (n = 10 657), CMVi incidence was 14.5 per 1000 (95% CI = 12.2-16.7). In multivariate logistic regression models adjusting for maternal age, CMVi was significantly associated with having one or more prior live births (odds ratio [OR]: 3.8 [95% CI: 2.6-5.4]) and having a child less than 6 years of age (OR: 4.3 [95%CI: 3.0-6.1]). One in three pregnant women in Israel is at risk for primary CMVi. This study demonstrates that real-world electronic healthcare data can be leveraged to support clinical management and development of interventions for congenital CMV by identifying women at high risk for CMVi during pregnancy.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
713-719Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The “silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013;26(1):86-102.
Demmler-Harrison G, Weisman L. Congenital cytomegalovirus infection: clinical features and diagnosis. UpToDate. 2019
Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007;17(4):253-276.
Britt WJ. Maternal immunity and the natural history of congenital human cytomegalovirus infection. Viruses. 2018;10(8):405.
Leruez-Ville M, Foulon I, Pass R, Ville Y. Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol. 2020;223(3):330-349.
Hyde TB, Schmid DS, Cannon MJ. Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV. Rev Med Virol. 2010;20(5):311-326.
Barlinn R, Dudman SG, Trogstad L, et al. Maternal and congenital cytomegalovirus infections in a population-based pregnancy cohort study. APMIS. 2018;126(12):899-906.
Silvano P, Riccardo P, Mariangela P, Michela D, Lucia P, Massimo S. Systematic serological cytomegalovirus screening in pregnancy: seroprevalence, seroconversion and frequency of congenital cytomegalovirus infection from 2007 to 2016. J Nurs Midwifery. 2020;1(1):002.
Lamarre V, Gilbert NL, Rousseau C, Gyorkos TW, Fraser WD. Seroconversion for cytomegalovirus infection in a cohort of pregnant women in Quebec, 2010-2013. Epidemiol Infect. 2016;144(8):1701-1709.
Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis. 2007;7:71.
Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis. 2006;43(9):1143-1151.
OECD. Fertility rates (indicator). 2019.
Rubin L, Belmaker I, Somekh E, et al. Maternal and child health in Israel: building lives. Lancet. 2017;389(10088):2514-2530.
Beloosesky R, Feldblum I, Shrim A, et al. Trends in continuity of pregnancy in women with positive cytomegalovirus IgM during the first trimester, 2008-2009. Isr Med Assoc J. 2017;19(8):484-488.
Cohen R, Damari N. Membership in Health Funds in 2017. Israel National Insurance Institute; 2018. https://www.btl.gov.il/Publications/survey/Pages/seker_303.aspx
Israel Central Bureau of Statistics. Characterization and classification of geographic units by the socio-economic level of the population 2008. Publication No. 1530, Jerusalem, Israel, 2013.
Schlesinger Y, Reich D, Eidelman AI, Schimmel MS, Hassanin J, Miron D. Congenital cytomegalovirus infection in Israel: screening in different subpopulations. Isr Med Assoc J. 2005;7(4):237-240.
Njue A, Coyne C, Margulis AV, et al. The role of congenital cytomegalovirus infection in adverse birth outcomes: a review of the potential mechanisms. Viruses. 2020;13(1):20.
Matcho A, Ryan P, Fife D, Gifkins D, Knoll C, Friedman A. Inferring pregnancy episodes and outcomes within a network of observational databases. PLoS One. 2018;13(2):e0192033.
Devine S, West S, Andrews E, et al. The identification of pregnancies within the general practice research database. Pharmacoepidemiol Drug Safety. 2010;19(1):45-50.
Naleway AL, Gold R, Kurosky S, et al. Identifying pregnancy episodes, outcomes, and mother-infant pairs in the Vaccine Safety Datalink. Vaccine. 2013;31(27):2898-2903.
Hornbrook MC, Whitlock EP, Berg CJ, et al. Development of an algorithm to identify pregnancy episodes in an integrated health care delivery system. Health Serv Res. 2007;42(2):908-927.
Baldwin E, Johnson K, Berthoud H, Dublin S. Linking mothers and infants within electronic health records: a comparison of deterministic and probabilistic algorithms. Pharmacoepidemiol Drug Safety. 2015;24(1):45-51.
Ryckman KK, Berberich SL, Dagle JM. Predicting gestational age using neonatal metabolic markers. Am J Obstet Gynecol. 2016;214(4):e511-e515.
MacDonald SC, Cohen JM, Panchaud A, McElrath TF, Huybrechts KF, Hernandez-Diaz S. Identifying pregnancies in insurance claims data: methods and application to retinoid teratogenic surveillance. Pharmacoepidemiol Drug Saf. 2019;28(9):1211-1221.
Chatzakis C, Ville Y, Makrydimas G, Dinas K, Zavlanos A, Sotiriadis A. Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences. Am J Obstet Gynecol. 2020;223:870-883.
Revello MG, Tibaldi C, Masuelli G, et al. Prevention of primary cytomegalovirus infection in pregnancy. EBioMedicine. 2015;2(9):1205-1210.